Citations (42)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Christopher J Hostler & Luke F Chen. (2013)
Fidaxomicin for treatment of clostridium difficile-associated diarrhea and its potential role for prophylaxis. Expert Opinion on Pharmacotherapy 14:11, pages 1529-1536.
Read now
Read now
Chaitanya Pant, Abhishek Deshpande, Muhammad A. Altaf, Anil Minocha & Thomas J. Sferra. (2013) Clostridium difficile infection in children: a comprehensive review. Current Medical Research and Opinion 29:8, pages 967-984.
Read now
Read now
Melina Kachrimanidou & Nikolaos Malisiovas. (2011) Clostridium difficile Infection: A Comprehensive Review. Critical Reviews in Microbiology 37:3, pages 178-187.
Read now
Read now
Articles from other publishers (39)
Caio T Heleno, Aleksey Tagintsev, Katharine Lasley & Douglas Summerfield. (2021) Fidaxomicin as a Salvage Therapy for Fulminant Clostridioides difficile Infection. Cureus.
Crossref
Crossref
David Dailler, Andrea Dorst, Daniel Schäfle, Peter Sander & Karl Gademann. (2021) Novel fidaxomicin antibiotics through site-selective catalysis. Communications Chemistry 4:1.
Crossref
Crossref
Nader S. Abutaleb & Mohamed N. Seleem. (2021) In vivo efficacy of auranofin in a hamster model of Clostridioides difficile infection. Scientific Reports 11:1.
Crossref
Crossref
Norbert Lügering & Andreas Stallmach. 2021. Therapie-Handbuch - Gastroenterologie und Hepatologie. Therapie-Handbuch - Gastroenterologie und Hepatologie
179
183
.
Adenrele Oludiran, David S. Courson, Malia D. Stuart, Anwar R. Radwan, John C. Poutsma, Myriam L. Cotten & Erin B. Purcell. (2019) How Oxygen Availability Affects the Antimicrobial Efficacy of Host Defense Peptides: Lessons Learned from Studying the Copper-Binding Peptides Piscidins 1 and 3. International Journal of Molecular Sciences 20:21, pages 5289.
Crossref
Crossref
N. Lügering & W. Domschke. 2019. Therapie-Handbuch. Therapie-Handbuch
224
227
.
Tanaji T. Talele. (2017)
Natural-Products-Inspired Use of the
gem
-Dimethyl Group in Medicinal Chemistry
. Journal of Medicinal Chemistry 61:6, pages 2166-2210.
Crossref
Crossref
Hsiao-Ting Yang, Jenn-Wei Chen, Jagat Rathod, Yu-Zhen Jiang, Pei-Jane Tsai, Yuan-Pin Hung, Wen-Chien Ko, Daniel Paredes-Sabja & I-Hsiu Huang. (2018) Lauric Acid Is an Inhibitor of Clostridium difficile Growth in Vitro and Reduces Inflammation in a Mouse Infection Model. Frontiers in Microbiology 8.
Crossref
Crossref
N. Lügering & W. Domschke. 2018. Therapie-Handbuch. Therapie-Handbuch
392
395
.
Michael J. Aldape, Aaron E. PackhamDustin D. HeeneySavannah N. Rice, Amy E. Bryant & Dennis L. Stevens. (2017) Fidaxomicin reduces early toxin A and B production and sporulation in Clostridium difficile
in vitro. Journal of Medical Microbiology 66:10, pages 1393-1399.
Crossref
Crossref
Erin B. Purcell, Robert W. McKee, David S. Courson, Elizabeth M. Garrett, Shonna M. McBride, Richard E. Cheney & Rita Tamayo. (2017) A Nutrient-Regulated Cyclic Diguanylate Phosphodiesterase Controls Clostridium difficile Biofilm and Toxin Production during Stationary Phase. Infection and Immunity 85:9.
Crossref
Crossref
. 2017. Understanding the Gut Microbiota. Understanding the Gut Microbiota
115
137
.
Erin B. Purcell & Rita Tamayo. (2016) Cyclic diguanylate signaling in Gram-positive bacteria. FEMS Microbiology Reviews 40:5, pages 753-773.
Crossref
Crossref
Erin B. Purcell, Robert W. McKee, Eric Bordeleau, Vincent Burrus & Rita Tamayo. (2016) Regulation of Type IV Pili Contributes to Surface Behaviors of Historical and Epidemic Strains of Clostridium difficile. Journal of Bacteriology 198:3, pages 565-577.
Crossref
Crossref
Yasmeen Vincent, Arif Manji, Kathleen Gregory-Miller & Christine Lee. (2015) A Review of Management of Clostridium difficile Infection: Primary and Recurrence. Antibiotics 4:4, pages 411-423.
Crossref
Crossref
N. Lügering & W. Domschke. 2015. Therapie-Handbuch Grundwerk inkl 6. Lfg.. Therapie-Handbuch Grundwerk inkl 6. Lfg.
1
3
.
Veroljub Marković, Marina Kostić, Ivana Iličković & Slobodan M. Janković. (2014) Cost-Effectiveness Comparison of Fidaxomicin and Vancomycin for Treatment of Clostridium difficile Infection: A Markov Model Based on Data from a South West Balkan Country in Socioeconomic Transition. Value in Health Regional Issues 4, pages 87-94.
Crossref
Crossref
M. Gacto, M. Madrid, A. Franco, T. Soto, J. Cansado & J. Vicente-Soler. 2014. Antimicrobial Compounds. Antimicrobial Compounds
149
175
.
Victor O. Badger, Nate A. Ledeboer, Mary Beth Graham & Charles E. EdmistonJr.Jr.. (2012)
Clostridium difficile
. Journal of Parenteral and Enteral Nutrition 36:6, pages 645-662.
Crossref
Crossref
Ed T. Buurman, Melinda A. Foulk, Ning Gao, Valerie A. Laganas, David C. McKinney, Demetri T. Moustakas, Jonathan A. Rose, Adam B. Shapiro & Paul R. Fleming. (2012) Novel Rapidly Diversifiable Antimicrobial RNA Polymerase Switch Region Inhibitors with Confirmed Mode of Action in Haemophilus influenzae. Journal of Bacteriology 194:20, pages 5504-5512.
Crossref
Crossref
Ujjini Manjunatha*Fumiaki Yokokawa, Meera Gurumurthy & Thomas Dick. 2012. Drug Discovery from Natural Products. Drug Discovery from Natural Products
307
325
.
O. A. Cornely, M. A. Miller, T. J. Louie, D. W. Crook & S. L. Gorbach. (2012) Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin. Clinical Infectious Diseases 55:suppl 2, pages S154-S161.
Crossref
Crossref
Farah Babakhani, Laurent Bouillaut, Abraham Gomez, Pamela Sears, Ly Nguyen & Abraham L. Sonenshein. (2012) Fidaxomicin Inhibits Spore Production in Clostridium difficile. Clinical Infectious Diseases 55:suppl_2, pages S162-S169.
Crossref
Crossref
Diane M. Citron, Kerin L. Tyrrell, C. Vreni Merriam & Ellie J. C. Goldstein. (2012)
Comparative
In Vitro
Activities of LFF571 against Clostridium difficile and 630 Other Intestinal Strains of Aerobic and Anaerobic Bacteria
. Antimicrobial Agents and Chemotherapy 56:5, pages 2493-2503.
Crossref
Crossref
Kayla R. Stover, Daniel M. Riche, Christie L. Gandy & Harold Henderson. (2012) What Would We Do Without Metronidazole?. The American Journal of the Medical Sciences 343:4, pages 316-319.
Crossref
Crossref
Diane M. Citron, Kerin L. Tyrrell, C. Vreni Merriam & Ellie J. C. Goldstein. (2012)
In Vitro
Activities of CB-183,315, Vancomycin, and Metronidazole against 556 Strains of Clostridium difficile, 445 Other Intestinal Anaerobes, and 56 Enterobacteriaceae Species
. Antimicrobial Agents and Chemotherapy 56:3, pages 1613-1615.
Crossref
Crossref
A. A. Venugopal & S. Johnson. (2011) Fidaxomicin: A Novel Macrocyclic Antibiotic Approved for Treatment of Clostridium difficile Infection. Clinical Infectious Diseases 54:4, pages 568-574.
Crossref
Crossref
Andrea Lo Vecchio & George M. Zacur. (2012) Clostridium difficile infection. Current Opinion in Gastroenterology 28:1, pages 1-9.
Crossref
Crossref
Joanne Bronson, Murali Dhar, William Ewing & Nils Lonberg. 2012. Annual Reports in Medicinal Chemistry Volume 47. Annual Reports in Medicinal Chemistry Volume 47
499
569
.
C. S. Pitchumoni, C. S. Pitchumoni, C. S. Pitchumoni, T. S. Dharmarajan, T. S. Dharmarajan, T. S. Dharmarajan & T. S. Dharmarajan. 2012. Geriatric Gastroenterology. Geriatric Gastroenterology
519
526
.
Linda D. Bobo, Erik R. Dubberke & Marin Kollef. (2011) Clostridium difficile in the ICU. Chest 140:6, pages 1643-1653.
Crossref
Crossref
Chaitanya Pant, Thomas J. Sferra, Abhishek Deshpande & Anil Minocha. (2011) Clinical approach to severe Clostridium difficile infection: Update for the hospital practitioner. European Journal of Internal Medicine 22:6, pages 561-568.
Crossref
Crossref
Aashish Srivastava, Meliza Talaue, Shuang Liu, David Degen, Richard Y Ebright, Elena Sineva, Anirban Chakraborty, Sergey Y Druzhinin, Sujoy Chatterjee, Jayanta Mukhopadhyay, Yon W Ebright, Alex Zozula, Juan Shen, Sonali Sengupta, Rui Rong Niedfeldt, Cai Xin, Takushi Kaneko, Herbert Irschik, Rolf Jansen, Stefano Donadio, Nancy Connell & Richard H Ebright. (2011) New target for inhibition of bacterial RNA polymerase: ‘switch region’. Current Opinion in Microbiology 14:5, pages 532-543.
Crossref
Crossref
Farah Babakhani, Abraham Gomez, Nikki Robert & Pamela Sears. (2011) Postantibiotic Effect of Fidaxomicin and Its Major Metabolite, OP-1118, against Clostridium difficile. Antimicrobial Agents and Chemotherapy 55:9, pages 4427-4429.
Crossref
Crossref
Farah Babakhani, Abraham Gomez, Nikki Robert & Pamela Sears. (2011) Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile. Journal of Medical Microbiology 60:8, pages 1213-1217.
Crossref
Crossref
Claire M.F. van Nispen tot Pannerden, Annelies Verbon & Ernst J. Kuipers. (2011) Recurrent Clostridium difficile Infection. Drugs 71:7, pages 853-868.
Crossref
Crossref
Ashwin N. Ananthakrishnan. (2010) Clostridium difficile infection: epidemiology, risk factors and management. Nature Reviews Gastroenterology & Hepatology 8:1, pages 17-26.
Crossref
Crossref
John G. Bartlett. (2010) Clostridium difficile: progress and challenges. Annals of the New York Academy of Sciences 1213:1, pages 62-69.
Crossref
Crossref
Gerald W. Tannock, Karen Munro, Corinda Taylor, Blair Lawley, Wayne Young, Brendan Byrne, Judy Emery & Thomas Louie. (2010) A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Microbiology 156:11, pages 3354-3359.
Crossref
Crossref